Asahi, Actelion Throw Final Punches In Fasudil IP Row

Law360, New York (April 27, 2011, 7:57 PM EDT) -- Asahi Kasei Pharma Corp. urged a California jury on Wednesday to order Actelion Ltd. to pay hundreds of millions of dollars in damages for edging Fasudil out of the market by interfering with Asahi's license agreement with CoTherix Inc. to develop the hypertension drug, which was allegedly sidelined for safety reasons.

The closing arguments in the Superior Court of the State of California, County of San Mateo, came as the trial — which has been ongoing for three months — has grown increasingly bitter, with lawyers...
To view the full article, register now.